halia therapeutics
-
Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement.
-
Halia Therapeutics Expands to Abu Dhabi
Halia Therapeutics Expands to Abu Dhabi
-
Halia Therapeutics Named as 2025 Top 10 Longevity Breakthrough Award Winner
Halia Therapeutics Named as 2025 Top 10 Longevity Breakthrough Award Winner
-
Halia Therapeutics Published in Journey of Drug Targeting
Halia Therapeutics Published in Journey of Drug Targeting
-
Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer’s and other neurodegenerative diseases.
-
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
-
M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE
Trial underscores IROS’s commitment to developing innovative therapies for unmet medical needs
-
The Future Of Inflammation: The Inflammasome And Beyond
Novel targets for managing inflammation hold the promise of greater efficacy and safety for diseases not widely viewed…
-
Halia CEO, David Bearss, on Challenges Posed by FDA Project Optimus
Halia Therapeutics’ CEO, David Bearss, recently discussed the FDA’s Project Optimus in The Wall Street Journal.
-
Halia Therapeutics to Unveil New Clinical Program Targeting the LRRK2 Protein for Alzheimer’s Disease at Discovery Europe 2024
Dr. Bearss will be the Chair of the “Drug Discovery for Neurodegenerative Diseases” session, on May 23.
-
BioTech Nation Podcast: Fighting Inflammation, and Alzheimer’s: Dr. David Bearss, President & CEO Halia Therapeutics
BioTech Nation Podcast: Fighting Inflammation, and Alzheimer’s: Dr. David Bearss, President & CEO Halia Therapeutics
-
Halia Therapeutics to Present at BIO-Europe Spring 2024 Conference
Presentation to be held on Tuesday, March 19, from 11:30 a.m. – 11:45 a.m. CET
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
